Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALKS NASDAQ:LGND NASDAQ:MNKD NASDAQ:RGEN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$26.52-1.7%$28.17$25.17▼$36.45$4.38B0.531.80 million shs1.96 million shsLGNDLigand Pharmaceuticals$165.51-0.1%$146.09$93.58▼$169.49$3.24B0.96150,812 shs315,457 shsMNKDMannKind$5.38-3.4%$4.19$3.38▼$7.63$1.65B1.022.78 million shs6.17 million shsRGENRepligen$113.74+0.2%$120.73$102.96▼$182.52$6.40B1.07773,668 shs647,059 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-9.92%-7.16%-8.33%-2.49%LGNDLigand Pharmaceuticals0.00%-0.60%+9.71%+44.12%+58.20%MNKDMannKind0.00%+0.54%+49.33%+46.19%-11.16%RGENRepligen0.00%-8.85%-8.69%-9.95%-18.89%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALKSAlkermes$26.52-1.7%$28.17$25.17▼$36.45$4.38B0.531.80 million shs1.96 million shsLGNDLigand Pharmaceuticals$165.51-0.1%$146.09$93.58▼$169.49$3.24B0.96150,812 shs315,457 shsMNKDMannKind$5.38-3.4%$4.19$3.38▼$7.63$1.65B1.022.78 million shs6.17 million shsRGENRepligen$113.74+0.2%$120.73$102.96▼$182.52$6.40B1.07773,668 shs647,059 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALKSAlkermes0.00%-9.92%-7.16%-8.33%-2.49%LGNDLigand Pharmaceuticals0.00%-0.60%+9.71%+44.12%+58.20%MNKDMannKind0.00%+0.54%+49.33%+46.19%-11.16%RGENRepligen0.00%-8.85%-8.69%-9.95%-18.89%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALKSAlkermes 2.92Moderate Buy$41.8558.21% UpsideLGNDLigand Pharmaceuticals 3.00Buy$176.506.51% UpsideMNKDMannKind 3.17Buy$11.17108.53% UpsideRGENRepligen 2.67Moderate Buy$166.6746.59% UpsideCurrent Analyst Ratings BreakdownLatest MNKD, RGEN, ALKS, and LGND Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025RGENRepligenJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetHold$145.00 ➝ $135.009/9/2025ALKSAlkermesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$43.009/9/2025ALKSAlkermesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$34.00 ➝ $35.009/9/2025ALKSAlkermesHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$46.009/5/2025MNKDMannKindOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$12.00 ➝ $15.009/3/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/3/2025LGNDLigand PharmaceuticalsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$167.00 ➝ $190.009/3/2025MNKDMannKindWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$9.00 ➝ $10.009/3/2025RGENRepligenHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$180.009/2/2025RGENRepligenRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$205.009/2/2025ALKSAlkermesWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$44.00(Data available from 9/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALKSAlkermes$1.51B2.90$2.60 per share10.17$9.05 per share2.92LGNDLigand Pharmaceuticals$187.58M17.31$1.61 per share103.15$43.95 per share3.77MNKDMannKind$301.74M5.45$0.13 per share40.13($0.29) per share-18.47RGENRepligen$673.96M9.49$3.11 per share36.55$35.21 per share3.23Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALKSAlkermes$367.07M$2.0812.7219.311.5223.15%24.86%17.14%10/23/2025 (Estimated)LGNDLigand Pharmaceuticals-$4.03M-$4.00N/A44.66N/A-40.44%-9.21%-8.09%11/6/2025 (Estimated)MNKDMannKind$27.59M$0.1148.6923.28N/A10.87%-32.60%7.81%11/6/2025 (Estimated)RGENRepligen-$25.51M-$0.25N/A48.182.09-2.05%4.61%3.24%11/11/2025 (Estimated)Latest MNKD, RGEN, ALKS, and LGND EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025LGNDLigand Pharmaceuticals$1.54$1.60+$0.06$0.24$43.87 million$47.63 million8/6/2025Q2 2025MNKDMannKind$0.04$0.05+$0.01N/A$77.82 million$76.53 million7/29/2025Q2 2025ALKSAlkermes$0.42$0.52+$0.10$0.52$343.20 million$390.66 million7/29/2025Q2 2025RGENRepligen$0.40$0.37-$0.03$0.26$174.62 million$182.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALKSAlkermesN/AN/AN/AN/AN/ALGNDLigand PharmaceuticalsN/AN/AN/AN/AN/AMNKDMannKindN/AN/AN/AN/AN/ARGENRepligenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALKSAlkermesN/A3.232.85LGNDLigand PharmaceuticalsN/A5.455.21MNKDMannKindN/A2.502.24RGENRepligen0.268.597.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALKSAlkermes95.21%LGNDLigand Pharmaceuticals91.28%MNKDMannKind49.55%RGENRepligen97.64%Insider OwnershipCompanyInsider OwnershipALKSAlkermes4.40%LGNDLigand Pharmaceuticals7.00%MNKDMannKind2.70%RGENRepligen1.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALKSAlkermes1,800165.08 million157.82 millionOptionableLGNDLigand Pharmaceuticals8019.60 million18.23 millionOptionableMNKDMannKind400306.83 million297.62 millionOptionableRGENRepligen1,77856.26 million55.58 millionOptionableMNKD, RGEN, ALKS, and LGND HeadlinesRecent News About These CompaniesWoodline Partners LP Buys New Shares in Repligen Corporation $RGENSeptember 15 at 4:00 AM | marketbeat.comRepligen (NASDAQ:RGEN) Given New $135.00 Price Target at Jefferies Financial GroupSeptember 14 at 8:14 AM | marketbeat.comOsterweis Capital Management Inc. Has $9.26 Million Position in Repligen Corporation $RGENSeptember 14 at 5:57 AM | marketbeat.comJefferies Financial Group Has Lowered Expectations for Repligen (NASDAQ:RGEN) Stock PriceSeptember 14 at 3:30 AM | americanbankingnews.comUnited Services Automobile Association Acquires New Shares in Repligen Corporation $RGENSeptember 13 at 4:27 AM | marketbeat.comWhy Repligen (RGEN) Stock Is Down TodaySeptember 12 at 7:48 PM | msn.comIs There An Opportunity With Repligen Corporation's (NASDAQ:RGEN) 29% Undervaluation?September 10, 2025 | uk.finance.yahoo.comRBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)September 10, 2025 | theglobeandmail.comFred Alger Management LLC Boosts Position in Repligen Corporation $RGENSeptember 10, 2025 | marketbeat.comDynamic Technology Lab Private Ltd Raises Stake in Repligen Corporation $RGENSeptember 10, 2025 | marketbeat.comScientech Research LLC Makes New Investment in Repligen Corporation $RGENSeptember 9, 2025 | marketbeat.comRepligen Corporation $RGEN Shares Sold by Polar Asset Management Partners Inc.September 9, 2025 | marketbeat.comSandler Capital Management Sells 8,004 Shares of Repligen Corporation $RGENSeptember 8, 2025 | marketbeat.comCinctive Capital Management LP Sells 59,424 Shares of Repligen Corporation $RGENSeptember 8, 2025 | marketbeat.comGranahan Investment Management LLC Trims Stake in Repligen Corporation $RGENSeptember 7, 2025 | marketbeat.comEFG Asset Management North America Corp. Has $1.65 Million Stake in Repligen Corporation $RGENSeptember 7, 2025 | marketbeat.comAlliancebernstein L.P. Purchases 13,284 Shares of Repligen Corporation $RGENSeptember 7, 2025 | marketbeat.comAlyeska Investment Group L.P. Boosts Holdings in Repligen Corporation $RGENSeptember 6, 2025 | marketbeat.comRepligen (NASDAQ:RGEN) Given "Buy" Rating at HC WainwrightSeptember 6, 2025 | americanbankingnews.comRepligen (NASDAQ:RGEN) Earns "Buy" Rating from HC WainwrightSeptember 5, 2025 | marketbeat.comAWM Investment Company Inc. Cuts Stock Holdings in Repligen Corporation $RGENSeptember 5, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025Alphabet’s Resurgence: It's Now a Clear Market LeaderBy Ryan Hasson | September 2, 2025MNKD, RGEN, ALKS, and LGND Company DescriptionsAlkermes NASDAQ:ALKS$26.52 -0.45 (-1.67%) Closing price 04:00 PM EasternExtended Trading$26.54 +0.02 (+0.08%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Ligand Pharmaceuticals NASDAQ:LGND$165.51 -0.24 (-0.14%) Closing price 04:00 PM EasternExtended Trading$165.31 -0.20 (-0.12%) As of 06:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.MannKind NASDAQ:MNKD$5.38 -0.19 (-3.41%) Closing price 04:00 PM EasternExtended Trading$5.36 -0.01 (-0.28%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.Repligen NASDAQ:RGEN$113.74 +0.20 (+0.18%) Closing price 04:00 PM EasternExtended Trading$116.00 +2.26 (+1.99%) As of 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Adobe’s Rebound Has Room to Run: 25% Upside by Year-End Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
